NFE2L2 and cancer: In the literature, the expression level of Nrf2 correlates with ferroptosis sensitivity, as cancer cells with downregulated Nrf2 are susceptible to pro-ferroptotic pharmaceuticals, whilst overexpression of Nrf2 prevents the initiation and execution of ferroptosis.